Patents by Inventor Scott C. Chappel
Scott C. Chappel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170008920Abstract: Described herein, in certain embodiments, are steroidal derivatives, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat androgen receptor mediated diseases or conditions.Type: ApplicationFiled: September 22, 2016Publication date: January 12, 2017Inventors: Scott C. Chappel, David S. Casebier
-
Publication number: 20120282331Abstract: Described herein, in certain embodiments, are steroidal derivatives, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat androgen receptor mediated diseases or conditions.Type: ApplicationFiled: November 9, 2010Publication date: November 8, 2012Applicant: TOKAI PHARMACEUTICALS, INC.Inventors: Scott C. Chappel, David S. Casebier
-
Publication number: 20100075402Abstract: A hybrid protein includes two coexpressed amino acid sequences forming a dimer. Each sequence contains the binding portion of a receptor, such as TBP1 or TBP2, or a ligand, such as IL-6, IFN-? and TPO, linked to a subunit of a natural heterodimeric scaffold. Each coexpressed sequence contains a corresponding subunit so as to form a heterodimer upon expression. Corresponding DNA molecules, expression vectors and host cells are also disclosed as are pharmaceutical compositions and a method of producing such proteins.Type: ApplicationFiled: September 26, 2007Publication date: March 25, 2010Applicant: LABORATOIRES SERONO SAInventors: Robert K. Campbell, Bradford A. Jameson, Scott C. Chappel
-
Publication number: 20090240039Abstract: A hybrid protein includes two coexpressed amino acid sequences forming a dimer. Each sequence contains the binding portion of a receptor, such as TBP1 or TBP2, or a ligand, such as IL-6, IFN-? and TPO, linked to a subunit of a natural heterodimeric scaffold. Each coexpressed sequence contains a corresponding subunit so as to form a heterodimer upon expression. Corresponding DNA molecules, expression vectors and host cells are also disclosed as are pharmaceutical compositions and a method of producing such proteins.Type: ApplicationFiled: October 30, 2007Publication date: September 24, 2009Inventors: Robert K. CAMPBELL, Bradford A. Jameson, Scott C. Chappel
-
Patent number: 7291339Abstract: A hybrid protein includes two coexpressed amino acid sequences forming a dimer. Each sequence contains the binding portion of a receptor, such as TBP1 or TBP2, or a ligand, such as IL-6, IFN-? and TPO, linked to ? subunit of a natural heterodimeric scaffold. Each coexpressed sequence contains a corresponding subunit so as to form a heterodimer upon expression. Corresponding DNA molecules, expression vectors and host cells are also disclosed as are pharmaceutical compositions and a method of producing such proteins.Type: GrantFiled: December 1, 2003Date of Patent: November 6, 2007Assignee: Laboratoires Serono SAInventors: Robert K. Campbell, Bradford A. Jameson, Scott C. Chappel
-
Publication number: 20040230034Abstract: A hybrid protein includes two coexpressed amino acid sequences forming a dimer. Each sequence contains the binding portion of a receptor, such as TBP1 or TBP2, or a ligand, such as IL-6, IFN-&bgr; and TPO, linked to &agr; subunit of a natural heterodimeric scaffold. Each coexpressed sequence contains a corresponding subunit so as to form a heterodimer upon expression. Corresponding DNA molecules, expression vectors and host cells are also disclosed as are pharmaceutical compositions and a method of producing such proteins.Type: ApplicationFiled: December 1, 2003Publication date: November 18, 2004Applicant: Applied Research Systems ARS Holding N.V.Inventors: Robert K. Campbell, Bradford A. Jameson, Scott C. Chappel
-
Patent number: 6663867Abstract: A hybrid protein includes two coexpressed amino acid sequences forming a dimer. Each sequence contains the binding portion of a receptor, such as TBP1 or TBP2, or a ligand, such as IL-6, IFN-&bgr; and TPO, linked to a subunit of a heterodimeric proteinaceous hormone, such as hCG. Each coexpressed sequence contains a corresponding hormone subunit so as to form a heterodimer upon expression. Corresponding DNA molecules, expression vectors and host cells are also disclosed as are pharmaceutical compositions and a method of producing such proteins.Type: GrantFiled: January 9, 2001Date of Patent: December 16, 2003Assignee: Applied Research Systems ARS Holding N.V.Inventors: Robert K. Campbell, Bradford A. Jameson, Scott C. Chappel
-
Patent number: 6348444Abstract: The invention relates to the use of human growth hormone for the manufacture of a medicament for stimulating hematopoiesis and immune reconstitution to be administered to a patient in need thereof about 30 days post-transplantation of hematopoietic stem cells.Type: GrantFiled: December 17, 1999Date of Patent: February 19, 2002Assignee: Applied Research Systems ARS Holding N.V.Inventor: Scott C. Chappel
-
Publication number: 20010014333Abstract: A hybrid protein includes two coexpressed amino acid sequences forming a dimer. Each sequence contains the binding portion of a receptor, such as TBP1 or TBP2, or a ligand, such as IL-6, IFN-&bgr; and TP0, linked to a subunit of a heterodimeric proteinaceous hormone, such as hCG. Each coexpressed sequence contains a corresponding hormone subunit so as to form a heterodimer upon expression. Corresponding DNA molecules, expression vectors and host cells are also disclosed as are pharmaceutical compositions and a method of producing such proteins.Type: ApplicationFiled: January 9, 2001Publication date: August 16, 2001Applicant: Applied Research Systems ARS Holding N.V.Inventors: Robert K. Campbell, Bradford A. Jameson, Scott C. Chappel
-
Patent number: 6194177Abstract: A hybrid protein includes two coexpressed amino acid sequences forming a dimer. Each sequence contains the binding portion of a receptor, such as TBP1 or TBP2, or a ligand, such as IL-6, IFN-&bgr;and TPO, linked to a subunit of a heterodimeric proteinaceous hormone, such as hCG. Each coexpressed sequence contains a corresponding hormone subunit so as to form a heterodimer upon expression. Corresponding DNA molecules, expression vectors and host cells are also disclosed as are pharmaceutical compositions and a method of producing such proteins.Type: GrantFiled: August 14, 1997Date of Patent: February 27, 2001Assignee: Applied Research Systems ARS Holding N.V.Inventors: Robert K. Campbell, Bradford A. Jameson, Scott C. Chappel
-
Patent number: 6193972Abstract: A hybrid protein includes two coexpressed amino acid sequences forming a dimer. Each sequence contains the binding portion of a receptor, such as TBP1 or TBP2, or a ligand, such as IL-6, IFN-&bgr; and TPO, linked to a subunit of a heterodimeric proteinaceous hormone, such as hCG. Each coexpressed sequence contains a corresponding hormone subunit so as to form a heterodimer upon expression. Corresponding DNA molecules, expression vectors and host cells are also disclosed as are pharmaceutical compositions and a method of producing such proteins.Type: GrantFiled: February 20, 1997Date of Patent: February 27, 2001Assignee: Applied Research Systems ARS Holding N.V.Inventors: Robert K. Campbell, Bradford A. Jameson, Scott C. Chappel
-
Patent number: 6096537Abstract: Cells suitable for transplantation which have at least two different epitopes on a surface antigen altered prior to transplantation to inhibit rejection of the cells following transplantation into an allogeneic or xenogeneic recipient are disclosed. These cells are more successfully transplanted than cells which have only a single epitope on the surface antigen altered. Preferably, the antigen on the cell surface which is altered is an MHC class I antigen. Two different epitopes on an MHC class I antigen can be altered by contacting the cell with two molecules, such as antibodies or fragments thereof (e.g., F(ab').sub.2 fragments), which bind to two different epitopes on the antigen. Preferred epitopes on human MHC class I antigens to be altered are epitopes recognized by the monoclonal antibodies W6/32 and PT85. Improved methods for transplantation utilizing cells which have at least two different epitopes on a surface antigen altered prior to transplantation are also disclosed.Type: GrantFiled: October 7, 1997Date of Patent: August 1, 2000Assignee: Diacrin, Inc.Inventor: Scott C. Chappel
-
Patent number: 5986068Abstract: Described are new glycoprotein hormones capable of competing with natural hormones for the normal receptor binding sites but substantially incapable of effecting post receptor activities. The glycoprotein hormones of the present invention have had specific (rather than all) oligosaccharide chains removed so as to effectively diminish biologic activity while not significantly reducing plasma half-life, thus improving the molecules effectiveness as an antagonist compared with conventionally-produced molecules. The preferred glycoprotein hormones are ideally obtained by site-directed mutagenesis to selectively deglycosylate the protein. Also described are therapeutic treatments comprising the administration of the recombinant glycoprotein hormones of the present invention as hormone antagonists.Type: GrantFiled: July 28, 1994Date of Patent: November 16, 1999Assignee: Applied Research Systems ARS Holding N.V.Inventors: Scott C. Chappel, Edward G. Bernstine
-
Patent number: 5705479Abstract: Described are new glycoprotein hormones capable of competing with natural hormones for the normal receptor binding sites but substantially incapable of effecting post receptor activities. The glycoprotein hormones of the present invention have had specific (rather than all) oligosaccharide chains removed so as to effectively diminish biologic activity while not significantly reducing plasma half-life, thus improving the molecules effectiveness as an antagonist compared with conventionally-produced molecules. The preferred glycoprotein hormones are ideally obtained by site-directed mutagenesis to selectively deglycosylate the protein. Also described are therapeutic treatments comprising the administration of the recombinant glycoprotein hormones of the present invention as hormone antagonists.Type: GrantFiled: May 17, 1995Date of Patent: January 6, 1998Assignee: Applied Research Systems ARS Holding N.V.Inventors: Scott C. Chappel, Edward G. Bernstine
-
Patent number: 5679340Abstract: Cells suitable for transplantation which have at least two different epitopes on a surface antigen altered prior to transplantation to inhibit rejection of the cells following transplantation into an allogeneic or xenogeneic recipient are disclosed. These cells are more successfully transplanted than cells which have only a single epitope on the surface antigen altered. Preferably, the antigen on the cell surface which is altered is an MHC class I antigen. Two different epitopes on an MHC class I antigen can be altered by contacting the cell with two molecules, such as antibodies or fragments thereof (e.g., F(ab').sub.2 fragments), which bind to two different epitopes on the antigen. Preferred epitopes on human MHC class I antigens to be altered are epitopes recognized by the monoclonal antibodies W6/32 and PT85. Improved methods for transplantation utilizing cells which have at least two different epitopes on a surface antigen altered prior to transplantation are also disclosed.Type: GrantFiled: May 10, 1994Date of Patent: October 21, 1997Assignee: Diacrin, Inc.Inventor: Scott C. Chappel
-
Patent number: 5674711Abstract: Cultured mammalian cells transfected with new vectors comprising full-length or partial .alpha. and .beta. subunit genomic DNA sequences produce significantly higher levels of dimeric glycoprotein hormone than do cells transfected with .alpha. and .beta. subunit cDNA sequences. In cases where only the cDNA clones are available, the cDNA sequences can be used in new expression vectors comprising introns or other important genomic regions from a homologous or heterologous source.Type: GrantFiled: July 23, 1993Date of Patent: October 7, 1997Assignee: Genzyme CorporationInventors: Christie A. Kelton, Noreen P. Nugent, Scott C. Chappel
-
Patent number: 5658760Abstract: Cultured mammalian cells transfected with new vectors comprising full-length or partial .alpha. and .beta. subunit genomic DNA sequences produce significantly higher levels of dimeric glycoprotein hormone than do cells transfected with .alpha. and .beta. subunit cDNA sequences. In cases where only the cDNA clones are available, the cDNA sequences can be used in new expression vectors comprising introns or other important genomic regions from a homologous or heterologous source.Type: GrantFiled: May 31, 1995Date of Patent: August 19, 1997Assignee: Genzyme CorporationInventors: Christie A. Kelton, Noreen P. Nugent, Scott C. Chappel
-
Patent number: 5635475Abstract: Described are new glycoprotein hormones capable of competing with natural hormones for the normal receptor binding sites but substantially incapable of effecting post receptor activities. The glycoprotein hormones of the present invention have had specific (rather than all) oligosaccharide chains removed so as to effectively diminish biologic activity while not significantly reducing plasma half-life, thus improving the molecules effectiveness as an antagonist compared with conventionally-produced molecules. The preferred glycoprotein hormones are ideally obtained by site-directed mutagenesis to selectively deglycosylate the protein. Also described are therapeutic treatments comprising the administration of the recombinant glycoprotein hormones of the present invention as hormone antagonists.Type: GrantFiled: May 16, 1995Date of Patent: June 3, 1997Assignee: Applied Research Systems ARS Holding N.V.Inventors: Scott C. Chappel, Edward G. Bernstine
-
Patent number: 5602006Abstract: Cultured mammalian cell transfected with new vectors comprising full-length or partial .alpha. and .beta. subunit genomic DNA sequences produce significantly higher levels of dimeric glycoprotein hormone than do cells transfected with .alpha. and .beta. subunit cDNA sequences. In cases where only the cDNA clones are available, the cDNA sequences can be used in new expression vectors comprising introns or other important genomic regions from a homologous or heterologous source.Type: GrantFiled: May 31, 1995Date of Patent: February 11, 1997Assignee: Genzyme CorporationInventors: Christie A. Kelton, Noreen P. Nugent, Scott C. Chappel
-
Patent number: 5352779Abstract: Described are new glycoprotein hormones capable of competing with natural hormones for the normal receptor binding sites but substantially incapable of effecting post receptor activities. The glycoprotein hormones of the present invention have had specific (rather than all) oligosaccharide chains removed so as to effectively diminish biologic activity while not significantly reducing plasma half-life, thus improving the molecules effectiveness as an antagonist compared with conventionally-produced molecules. The preferred glycoprotein hormones are ideally obtained by site-directed mutagenesis to selectively deglycosylate the protein. Also described are therapeutic treatments comprising the administration of the recombinant glycoprotein hormones of the present invention as hormone antagonists.Type: GrantFiled: September 23, 1993Date of Patent: October 4, 1994Assignee: Applied Research Systems ARS Holding N.V.Inventors: Scott C. Chappel, Edward G. Bernstine